🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementHypoglycemia risk with concomitant sulfonylurea use — my results so far

Hypoglycemia risk with concomitant sulfonylurea use — my results so far

mike.trainer_LA Thu, Apr 4, 2024 at 5:38 PM 34 replies 2,155 viewsPage 1 of 7
This thread is more than 26 months old. Information may be outdated. Consider searching for more recent discussions.
mike.trainer_LA
Senior Member
1,567
7,234
Apr 2024
Los Angeles, CA
Apr 4, 2024 at 5:38 PM#1

Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

What would genuinely help is knowing what distinguishes the nausea you can titrate through from the nausea that means stop.

I would rather have one careful answer than five confident ones.

37 7Dr.AddMedPHL, newstart_MO, mia_MS2 and 34 others
Reply Quote Save Share Report
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Apr 4, 2024 at 5:58 PM#2

Short answer first, then the reasoning. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

I would rather be corrected than agreed with, if it comes to it.

36 6Dr.PulmRoch, maya_sedona, stefan_berlin and 33 others
Reply Quote Save Share Report
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
Apr 4, 2024 at 6:18 PM#3
BethLabQueen said:
Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts.

Agreeing with BethLabQueen, and the qualification matters more than the agreement. The meal advice is right and incomplete without the hydration point. People stop drinking because drinking makes them feel full, then attribute dehydration symptoms to the drug.

35 5zoe_NC, Dr.ObesityLA, NurseKim_ATL and 32 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
sarah_nash92
Member
712
3,123
Jun 2024
Nashville, TN
Apr 4, 2024 at 6:38 PM#4
mike.trainer_LA said:
Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

This matches mine closely enough to be worth saying so. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

Last edited: Apr 5, 2024 at 12:38 AM
34 4CanadaChris, ZaraB_AL, JakeSmashed95 and 31 others
Reply Quote Save Share Report
jim_asheville
Member
289
1,234
Aug 2024
Asheville, NC
Apr 4, 2024 at 8:27 PM#5

Adding the clinical framing, because it changes how the question reads. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.

33 3LarryQC_SD, wanda_boise, NurseAsh_DET and 30 others
Reply Quote Save Share Report
1237

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register